AbbVie Completes $10.9 Billion Acquisition of Apogee Therapeutics
nashnova research
AbbVie closed its $10.9 billion acquisition of Apogee Therapeutics on Thursday — its largest bolt-on deal since 2019 — but the transaction will dilute earnings per share for years, with accretion not expected until 2032.
What did AbbVie actually buy?
AbbVie completed the roughly $10.9 billion acquisition of Apogee Therapeutics on Thursday.
Apogee's core value lies in its immunology and dermatology pipeline — making this AbbVie's largest bolt-on deal since 2019.
This means → AbbVie is stocking its post-Humira growth engine, betting big on next-generation skin and immune-disease drugs.
How much will near-term earnings take a hit?
The deal is expected to dilute adjusted EPS by roughly $0.14 in 2026 and $0.46 in 2027.
In plain terms = the price of buying Apogee gets spread across the income statement, thinning per-share profit for the next two years.
On top of that, IPR&D charges and milestone expenses tied to the deal have already produced a $0.58-per-share headwind through the second quarter.
Has full-year guidance changed?
AbbVie reaffirmed full-year 2026 adjusted diluted EPS guidance of $13.87–$14.07, versus a consensus of $14.01 — the range already absorbs the dilution.
Third-quarter adjusted EPS guidance stands at $3.84–$3.88, also in line with the Street.
This means → management views the short-term drag as fully baked in, with existing-business growth enough to offset it.
What is the real question hanging over the deal?
Accretion is not expected to begin until 2032 — dilution will weigh on EPS every year until then.
In plain terms = AbbVie spent $10.9 billion on a check that won't start paying off for six years.
The key market question: whether Apogee's pipeline can reach commercialization on schedule — any clinical setback or approval delay could leave the accretion promise unfulfilled.
市场有风险，内容仅供研究参考，不构成投资建议。